

*For immediate release*

**Fumiyoshi Sakai Joins Credit Suisse First Boston  
as Pharmaceuticals Analyst**

**Tokyo, July 14, 2005** -- Credit Suisse First Boston has announced that Fumiyoshi Sakai has joined the firm's Japanese Equity Research Department as the pharmaceuticals analyst, covering Japan's pharmaceuticals, healthcare and biotechnology companies.

Mr. Sakai joins CSFB from Deutsche Securities, where he worked as an analyst covering the Japanese pharmaceuticals sector since 2002. Prior to that, he worked for Societe Generale Securities and Yamaichi Research Institute of Securities and Economics. Mr. Sakai began his career at ICI, the British chemical company, after graduating from Arizona State University in 1981. He is currently ranked 4th by the 2005 Nikkei analyst survey and 7th by the 2005 Institutional Investor survey in the pharmaceuticals sector.

Today's appointment reflects CSFB's strong commitment to further strengthen its equity business in Japan.

###

Credit Suisse First Boston (CSFB) is the trade name for the investment banking business of Credit Suisse and its subsidiaries and affiliates. CSFB is a leading global investment bank serving institutional, corporate, government and individual clients. Its businesses include securities underwriting, sales and trading, investment banking, private equity, financial advisory services, investment research, venture capital, correspondent brokerage services and asset management. CSFB operates in 69 locations in 33 countries across five continents. CSFB is a division of the Zurich-based Credit Suisse Group, a leading global financial services company.

---

Press Contact: Isamu Kajino CSFB Tokyo 81 3 5404 9893